opioids U.S. Researchers Test Brain Implants to Treat Severe Opioid Addiction Medical researchers at West Virginia University are conducting the first U.S. clinical trial using deep brain simulation to combat treatment-resistant opioid addiction. The implanted device aims to monitor and curb addiction-related impulses in real time.
y combinator 82 Startups Showcase Innovations on Day Two of YC Summer 2019 Y Combinator wraps up its Summer 2019 Demo Days with 82 additional startups presenting disruptive solutions across biotech, logistics, and SaaS. The two-day event features a total of 166 companies aiming to transform their respective industries.
pathai PathAI Secures $60 Million for AI-Powered Disease Detection Technology PathAI raises $60 million to advance its computer vision technology that analyzes cell samples for diseases. The company currently focuses on pharmaceutical research while preparing for clinical trials within the next two years.
biotech Corporate Biotech Investors Double Down on Startup Funding in 2018 Corporate venture investors in the biotech sector participate in rounds valued at $8 billion in 2018, nearly doubling their 2017 totals. Corporate backers also sharply increase the funding amounts for rounds they directly lead.
fda FDA Approves First Major Depression Drug in Over 30 Years The FDA approves Johnson & Johnson's Spravato, an esketamine nasal spray for treatment-resistant depression. The fast-acting medication brings the first major breakthrough in depression treatment since the introduction of Prozac.
crisper China Officially Declares CRISPR Baby Experiment Illegal Chinese authorities rule that scientist He Jiankui acted illegally by creating gene-edited babies, citing his pursuit of personal fame and profit. The government promises severe punishment after revealing he fabricated ethics documents for the highly controversial experiment.
ai AI Startup Funding Booms Despite Murky Market Definitions Funding totals for AI startups grow year-over-year, but tracking the exact pace proves difficult due to inconsistent definitions of what actually constitutes an artificial intelligence company.
crispr J&J's $818 Million Bet Unlocks New Path for CRISPR Therapies Johnson & Johnson strikes an up to $818 million deal with Locus Biosciences to develop a unique CRISPR technology that destroys harmful bacterial DNA instead of editing it. The partnership focuses on treating respiratory and other organ infections while preserving the patient's healthy microbiome.